MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
Age≥18 years and≤70 years; [+9]
Previous treatment with targeted therapy, radiotherapy (radiotherapy to non-targ... [+20]